Literature DB >> 19924542

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Mohammad Tabrizi1, Gadi Gazit Bornstein, Hamza Suria.   

Abstract

The monoclonal antibody market continues to witness an impressive rate of growth and has become the leading source of expansion in the biologic segment within the pharmaceutical industry. Currently marketed monoclonal antibodies target a diverse array of antigens. These antigens are distributed in a variety of tissues such as tumors, lungs, synovial fluid, psoriatic plaques, and lymph nodes. As the concentration of drug at the proximity of the biological receptor determines the magnitude of the observed pharmacological responses, a significant consideration in effective therapeutic application of monoclonal antibodies is a thorough understanding of the processes that regulate antibody biodistribution. Monoclonal antibody distribution is affected by factors such as molecular weight, blood flow, tissue and tumor heterogeneity, structure and porosity, target antigen density, turnover rate, and the target antigen expression profile.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924542      PMCID: PMC2811642          DOI: 10.1208/s12248-009-9157-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  101 in total

Review 1.  The pharmacological basis of anti-IgE therapy.

Authors:  T W Chang
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

2.  Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.

Authors:  Herren Wu; David S Pfarr; Ying Tang; Ling-Ling An; Nita K Patel; Jeffry D Watkins; William D Huse; Peter A Kiener; James F Young
Journal:  J Mol Biol       Date:  2005-07-01       Impact factor: 5.469

Review 3.  Fcgamma receptors: old friends and new family members.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

4.  Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis.

Authors:  C I Westacott; A F Barakat; L Wood; M J Perry; P Neison; I Bisbinas; L Armstrong; A B Millar; C J Elson
Journal:  Osteoarthritis Cartilage       Date:  2000-05       Impact factor: 6.576

5.  Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort).

Authors:  Bruce W Kirkham; Marissa N Lassere; John P Edmonds; Katherine M Juhasz; Paul A Bird; C Soon Lee; Ron Shnier; Ian J Portek
Journal:  Arthritis Rheum       Date:  2006-04

6.  Role of extracellular matrix assembly in interstitial transport in solid tumors.

Authors:  P A Netti; D A Berk; M A Swartz; A J Grodzinsky; R K Jain
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

7.  IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.

Authors:  Rashid Deane; Abhay Sagare; Katie Hamm; Margaret Parisi; Barbra LaRue; Huang Guo; Zhenhua Wu; David M Holtzman; Berislav V Zlokovic
Journal:  J Neurosci       Date:  2005-12-14       Impact factor: 6.167

8.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation.

Authors:  A J Leu; D A Berk; A Lymboussaki; K Alitalo; R K Jain
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

9.  Openings between defective endothelial cells explain tumor vessel leakiness.

Authors:  H Hashizume; P Baluk; S Morikawa; J W McLean; G Thurston; S Roberge; R K Jain; D M McDonald
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 10.  Elimination mechanisms of therapeutic monoclonal antibodies.

Authors:  Mohammad A Tabrizi; Chih-Ming L Tseng; Lorin K Roskos
Journal:  Drug Discov Today       Date:  2006-01       Impact factor: 7.851

View more
  103 in total

1.  Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Authors:  Daniela Bumbaca; Hong Xiang; C Andrew Boswell; Ruediger E Port; Shannon L Stainton; Eduardo E Mundo; Sheila Ulufatu; Anil Bagri; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; Ben-Quan Shen
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 3.  Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

Authors:  Mohammad Tabrizi; Cherryl Funelas; Hamza Suria
Journal:  AAPS J       Date:  2010-07-24       Impact factor: 4.009

Review 4.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

5.  Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

Authors:  Yanguang Cao; Joseph P Balthasar; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-31       Impact factor: 2.745

Review 6.  Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.

Authors:  Colin Sheehan; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2019-10-15       Impact factor: 5.285

7.  Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.

Authors:  Christopher Geven; Dirk van Lier; Alice Blet; Roel Peelen; Bas Ten Elzen; Alexandre Mebazaa; Matthijs Kox; Peter Pickkers
Journal:  Br J Clin Pharmacol       Date:  2018-07-03       Impact factor: 4.335

Review 8.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 9.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

10.  Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics.

Authors:  Daniela Bumbaca Yadav; Vikas K Sharma; Charles Andrew Boswell; Isidro Hotzel; Devin Tesar; Yonglei Shang; Yong Ying; Saloumeh K Fischer; Jane L Grogan; Eugene Y Chiang; Konnie Urban; Sheila Ulufatu; Leslie A Khawli; Saileta Prabhu; Sean Joseph; Robert F Kelley
Journal:  J Biol Chem       Date:  2015-10-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.